Aileron Therapeutics to Participate in Fireside Chat at the William Blair Biotech Focus Conference 2021

Aileron Therapeutics Announces Initiation of Randomized, Double-Blind, Placebo-Controlled Trial of ALRN-6924 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

Aileron Therapeutics to be Added to the Russell Microcap® Index

Aileron Therapeutics to Host KOL Virtual Investor Event Discussing Opportunity for New Paradigm to Protect Cancer Patients from Chemotherapy-Induced Toxicities

Aileron Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update

Aileron Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Highlights

Aileron Therapeutics to Present at 2021 H.C. Wainwright Global Life Sciences Conference

Aileron Therapeutics Announces Enrollment Expansion for Upcoming Phase 1b Clinical Trial of ALRN-6924 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

Aileron Therapeutics Announces Completion of $35.9 Million Registered Direct Offering with Participation by New Fundamental Healthcare Investors Acorn Bioventures, BVF Partners, L.P. and Maven Investment Partners

Aileron Therapeutics Announces $35.9 Million Registered Direct Offering